Online inquiry

IVTScrip™ mRNA-Anti-GPNMB, CDX-011(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5659MR)

This product GTTS-WQ5659MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets GPNMB gene. The antibody can be applied in Breast Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001005340.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 10457
UniProt ID Q14956
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GPNMB, CDX-011(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ5659MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10722MR IVTScrip™ mRNA-Anti-FCGRT, M-281(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA M-281
GTTS-WQ8903MR IVTScrip™ mRNA-Anti-IGHE, IGE25(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IGE25
GTTS-WQ12438MR IVTScrip™ mRNA-Anti-IFNG, NI-0501(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA NI-0501
GTTS-WQ13994MR IVTScrip™ mRNA-Anti-GP, REGN-3470-3471-3479(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA REGN-3470-3471-3479
GTTS-WQ12888MR IVTScrip™ mRNA-Anti-TNF, OPRX-106(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA OPRX-106
GTTS-WQ11269MR IVTScrip™ mRNA-Anti-hly, MEDI4893(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI4893
GTTS-WQ13030MR IVTScrip™ mRNA-Anti-IFNAR, Peg-IFNA2 R23(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Peg-IFNA2 R23
GTTS-WQ8184MR IVTScrip™ mRNA-Anti-FCGRT, HL161(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA HL161
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW